News

Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.

In the past 12 months, the stock has nosedived more than 50%.

Hims & Hers Health and QXO face heavy short interest amid dilution and loss concerns, while KLA has slid nearly 40% since June as AI-driven chip spending fears grip semiconductor stocks.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

This blockbuster class of drugs is shattering all sales records. Which stock will do better—Eli Lilly or Novo Nordisk?

Morningstar maintained a ‘No Moat’ view, citing low telehealth barriers and offerings rivals can replicate “with relative ease.”

The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Telehealth platform disclosed users' "most private" health info and locked consumers into subscriptions, regulators allege.

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and

The agency alleges the telehealth company shared sensitive health data with Meta and Snap while deceiving users about charges and cancellations

According to the suit, Hims & Hers shared lists of certain customers, and the actions of visitors on its website, with advertisers such as Meta and Snap, even though it claimed its service maintains consumers’ privacy.

(Updates with Hims' official statement in the third paragraph.) Hims & Hers Health (HIMS) is bein

The U.S. Federal Trade Commission on Wednesday sued the telehealth company over allegations it shared sensitive user health data with advertisers.

Healthcare stocks were slightly lower Wednesday afternoon, with the NYSE Healthcare Index down 0.1%

Federal Trade Commission is suing Hims & Hers ‌alleging the telehealth platform shared users' health ‌data with online advertisers despite promising privacy and engaged in ​deceptive billing and cancellation practices, an FTC spokesperson said. Hims & Hers is one of the largest telehealth players in the market for weight loss drugs.

The U.S. Federal Trade Commission sued Hims & Hers on Wednesday alleging the telehealth platform shared ‌users' health data with online advertisers, despite promising privacy, and engaged ‌in deceptive billing and cancellation practices. Hims & Hers stock added to losses after ‌the news and was ⁠trading down around 12%. ⁠The company offers telehealth appointments and prescriptions for erectile dysfunction, hair loss, and mental health medications, which it ships straight to customers.

BlackRock disclosed ownership of 26.5 million HIMS shares, representing a stake of about 12%.

An FDA advisory panel backed six of seven peptides for possible inclusion on the 503A compounding list, with Emideltide the only rejection.

Joe Spector helped build a multibillion-dollar telehealth company. Now he’s on to own remote vet services.

Hims & Hers Health Inc. is in the spotlight Friday after an FDA advisory panel voted Thursday to recommend four key peptides be added to a federal list that would allow compounding pharmacies to legally produce them. FDA Panel Splits,...

A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million

Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the news means for HIMS stock.

Hims & Hers Health stock has delivered a very large 5 year gain, yet the latest valuation work suggests the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and supporting market multiples. Over 5 years, Hims & Hers Health has returned 312.9%, which puts the current debate squarely on whether earlier investors have already captured most of the value or if the rerating still has room to run. The outcome of the recent FDA peptide...

Earlier in July 2026, Hims & Hers Health announced that Chief Accounting Officer and Principal Accounting Officer Irene Becklund will resign effective October 9, 2026, with CFO Yemi Okupe temporarily assuming her responsibilities while the company searches for a permanent successor. Her departure coincides with an FDA advisory panel’s recommendation to ease compounding restrictions on peptides such as BPC-157, an area where Hims & Hers has been building capabilities through its own...

Hims & Hers Health (HIMS) is back in focus after an FDA advisory panel recommended allowing broader compounding of peptide BPC-157, a development tied directly to treatments offered through the company’s telehealth platform. See our latest analysis for Hims & Hers Health. Hims & Hers Health shares have been volatile over the past year, with a recent 3.35% 1 day share price gain following the FDA panel news set against a 1 year total shareholder return decline of 42.88%. The 3 year total...

The company gets most of its revenue from branded GLP-1s and other products. Most analysts see the stock fully valued.

The company gets most of its revenue from branded GLP-1s and other products. Most analysts see the stock fully valued.

Hims stock bounded higher Thursday after an FDA panel recommended compounding a popular peptide used in injury recovery.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.